tiprankstipranks
Advertisement
Advertisement

IL:CANF Stock Latest News

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
The FlyCan-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
20d ago
CANF
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
22d ago
CANF
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
PremiumThe Fly
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
2M ago
CANF
Can-Fite BioPharma completes enrollment in Piclidenoson study
PremiumThe Fly
Can-Fite BioPharma completes enrollment in Piclidenoson study
2M ago
CANF
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
3M ago
CANF
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
PremiumThe FlyCan-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
3M ago
CANF
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
Premium
The Fly
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
4M ago
CANF
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
Premium
The Fly
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
4M ago
CANF
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
PremiumThe Fly
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
4M ago
CANF
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
PremiumThe Fly
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
4M ago
CANF
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
PremiumThe Fly
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
5M ago
CANF
Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
PremiumThe Fly
Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
5M ago
CANF
Can-Fite BioPharma provides clinical, financial update
PremiumThe FlyCan-Fite BioPharma provides clinical, financial update
6M ago
CANF
Can-Fite BioPharma to participate in BioFIT 2025
Premium
The Fly
Can-Fite BioPharma to participate in BioFIT 2025
6M ago
CANF
Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602
Premium
The Fly
Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602
6M ago
CANF
Can-Fite announces 9-year survival with complete cure with Namodenoson
PremiumThe Fly
Can-Fite announces 9-year survival with complete cure with Namodenoson
7M ago
CANF
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
PremiumRatings
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
7M ago
CANF
Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
7M ago
CANF
Can-Fite BioPharma announces new findings for Namodenoson
PremiumThe Fly
Can-Fite BioPharma announces new findings for Namodenoson
9M ago
CANF
Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year
PremiumThe FlyCan-Fite BioPharma reports 1H EPS 0c vs. 0c last year
9M ago
CANF
Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
Premium
The Fly
Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
10M ago
CANF
Can-Fite BioPharma trading resumes
Premium
The Fly
Can-Fite BioPharma trading resumes
10M ago
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >